These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24308789)

  • 1. Pediatric formulation issues identified in Paediatric Investigation Plans.
    Quijano Ruiz B; Desfontaine E; Arenas-López S; Wang S
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):25-30. PubMed ID: 24308789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paediatric Drug Development and Formulation Design-a European Perspective.
    Van Riet-Nales DA; Kozarewicz P; Aylward B; de Vries R; Egberts TC; Rademaker CM; Schobben AF
    AAPS PharmSciTech; 2017 Feb; 18(2):241-249. PubMed ID: 27270905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reflection on the Pharmaceutical Formulation Challenges Associated with a Paediatric Investigation Plan for an Off-Patent Drug.
    Walsh J
    AAPS PharmSciTech; 2017 Feb; 18(2):250-256. PubMed ID: 27097815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.
    Walsh J; Cram A; Woertz K; Breitkreutz J; Winzenburg G; Turner R; Tuleu C;
    Adv Drug Deliv Rev; 2014 Jun; 73():14-33. PubMed ID: 24614069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric drug development: formulation considerations.
    Ali AA; Charoo NA; Abdallah DB
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Paediatric Formulation Initiative (EuPFI)-Formulating Ideas for Better Medicines for Children.
    Salunke S; Liu F; Batchelor H; Walsh J; Turner R; Ju TR; Tuleu C;
    AAPS PharmSciTech; 2017 Feb; 18(2):257-262. PubMed ID: 27422653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D
    Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory framework.
    Wang S
    Int J Pharm; 2015 Aug; 492(1-2):332-4. PubMed ID: 25959119
    [No Abstract]   [Full Text] [Related]  

  • 17. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population.
    Venables R; Batchelor H; Hodson J; Stirling H; Marriott J
    Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practices for selection of excipients for paediatrics - Workshop reflection.
    Salunke S; Clapham D; Agrawal A; Hughes K; Nunn T
    Eur J Pharm Biopharm; 2021 Mar; 160():77-81. PubMed ID: 33400989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.
    Lopez FL; Ernest TB; Tuleu C; Gul MO
    Expert Opin Drug Deliv; 2015; 12(11):1727-40. PubMed ID: 26165848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues impacting therapeutic outcomes in pediatric patients: an overview.
    Kalra A; Goindi S
    Curr Pediatr Rev; 2014; 10(3):184-93. PubMed ID: 25088338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.